The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The dark side of SOX2: cancer - a comprehensive overview
Open accessAbstract
// Erin L. Wuebben 1 and Angie Rizzino 1,2 1 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA 2 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA Correspondence to: Angie Rizzino, email: // Keywords : SOX2, cancer, tumor progression, tumor-initiating cells, cancer stem cell markers Received : December 20, 2016 Accepted : March 16, 2017 Published : March 25, 2017 Abstract The pluripotency-associated transcription factor SOX2 is essential during mammalian embryogenesis and later in life, but SOX2 expression can also be highly detrimental. Over the past 10 years, SOX2 has been shown to be expressed in at least 25 different cancers. This review provides a comprehensive overview of the roles of SOX2 in cancer and focuses on two broad topics. The first delves into the expression and function of SOX2 in cancer focusing on the connection between SOX2 levels and tumor grade as well as patient survival. As part of this discussion, we address the developing connection between SOX2 expression and tumor drug resistance. We also call attention to an under-appreciated property of SOX2, its levels in actively proliferating tumor cells appear to be optimized to maximize tumor growth - too little or too much SOX2 dramatically alters tumor growth. The second topic of this review focuses on the exquisite array of molecular mechanisms that control the expression and transcriptional activity of SOX2. In addition to its complex regulation at the transcriptional level, SOX2 expression and activity are controlled carefully by microRNAs, long non-coding RNAs, and post-translational modifications. In the Conclusion and Future Perspectives section, we point out that there are still important unanswered questions. Addressing these questions is expected to lead to new insights into the functions of SOX2 in cancer, which will help design novels strategies for more effectively treating some of the most deadly cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complex architecture and regulated expression of the Sox2ot locus during vertebrate development
Amaral, P. P., Neyt, C., Wilkins, S. J., Askarian-Amiri, M. E., Sunkin, S. M., Perkins, A. C., & Mattick, J. S. (2009) · RNA · doi:10.1261/rna.1705309 · Cited by 209
Cited by
The role of SOX family members in solid tumours and metastasis
Grimm, D., Bauer, J., Wise, P., Krüger, M., Simonsen, U., Wehland, M., Infanger, M., & Corydon, T. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.004 · Cited by 487
Live-cell imaging reveals enhancer-dependent Sox2 transcription in the absence of enhancer proximity
Alexander, J. M., Guan, J., Li, B., Maliskova, L., Song, M., Shen, Y., Huang, B., Lomvardas, S., & Weiner, O. D. (2019) · eLife · doi:10.7554/elife.41769 · Cited by 346
SOX2 in development and cancer biology
Novak, D., Hüser, L., Elton, J. J., Umansky, V., Altevogt, P., & Utikal, J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.007 · Cited by 328
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
Elmusrati, A., Wang, J., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00131-7 · Cited by 312
Metadata
- Authors
- Wuebben, E. L., & Rizzino, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-03-25
- Volume
- 8
- Issue
- 27
- Pages
- 44917-44943
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2599212387
- Cited by
- 222
- References
- 1
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The dark side of SOX2: cancer - a comprehensive overview. https://app.cochat.ai/papers/10.18632/oncotarget.16570
- The paper
- Wuebben, E. L., & Rizzino, A. (2017). The dark side of SOX2: cancer - a comprehensive overview. Oncotarget. https://doi.org/10.18632/oncotarget.16570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.